1.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 1995; 5 (1): 32-4
en Inglés
| IMEMR
| ID: emr-95777
RESUMEN
In an open, non-comparative trial efficacy and safety of Recombinant interferon alfa [INF alfa] given in 3 million units subcutaneously thrice weekly for 6 months was assessed in patients with chronic hepatitis C. A response rate of 58.7% at the end of treatment period and relapse rate of 47.4% after cessation of treatment was noted